Intra-Cellular Therapies Profit Margin 2013-2022 | ITCI
Current and historical gross margin, operating margin and net profit margin for Intra-Cellular Therapies (ITCI) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Intra-Cellular Therapies net profit margin as of September 30, 2022 is -158.39%.
|Intra-Cellular Therapies Annual Profit Margins
|Intra-Cellular Therapies Quarterly Profit Margins
||Medical - Biomedical and Genetics
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.